{"id":65539,"date":"2026-05-18T13:17:09","date_gmt":"2026-05-18T05:17:09","guid":{"rendered":"https:\/\/flcube.com\/?p=65539"},"modified":"2026-05-18T13:17:10","modified_gmt":"2026-05-18T05:17:10","slug":"shanghai-curegenes-cg-0255-receives-nmpa-clearance-for-ischemic-stroke-clinical-trial-first-thiol-based-p2y12-inhibitor-overcoming-clopidogrel-resistance","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=65539","title":{"rendered":"Shanghai CureGene&#8217;s CG-0255 Receives NMPA Clearance for Ischemic Stroke Clinical Trial \u2013 First Thiol-Based P2Y12 Inhibitor Overcoming Clopidogrel Resistance"},"content":{"rendered":"\n<p><strong>Shanghai CureGene Pharmaceutical Co., Ltd.<\/strong> announced that China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> has granted approval to initiate clinical studies evaluating <strong>CG-0255<\/strong>, a <strong>Category 1 innovative drug<\/strong>, for the treatment of <strong>ischemic stroke<\/strong>. The investigational therapy represents the <strong>world&#8217;s first P2Y12 receptor inhibitor<\/strong> based on a <strong>thiol-based prodrug design<\/strong>, available in both <strong>intravenous and oral formulations<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Clinical trial authorization (Category 1 innovative drug)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>CG-0255 (P2Y12 receptor inhibitor, thiol-based prodrug)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Ischemic stroke<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>18 May 2026<\/td><\/tr><tr><td><strong>Next Steps<\/strong><\/td><td>Phase I\/II clinical trials to assess safety, efficacy, and optimal dosing<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism-of-action\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> Next-generation antiplatelet agent with thiol-based prodrug design<\/li>\n\n\n\n<li><strong>Target:<\/strong> P2Y12 receptor (key mediator of platelet aggregation)<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> Single-step hydrolysis directly releases active metabolite, bypassing CYP2C19 metabolic pathway<\/li>\n\n\n\n<li><strong>Formulations:<\/strong> Dual availability \u2013 intravenous (acute setting) and oral (maintenance therapy)<\/li>\n\n\n\n<li><strong>Therapeutic Rationale:<\/strong> Addresses &#8220;clopidogrel resistance&#8221; affecting 30-50% of Asian populations due to CYP2C19 enzyme deficiency<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-advantages-over-existing-therapies\">Clinical Advantages Over Existing Therapies<\/h2>\n\n\n\n<p>Current P2Y12 inhibitors like clopidogrel require complex metabolic activation through the CYP2C19 enzyme pathway, leading to significant inter-patient variability and treatment failure in enzyme-deficient individuals.<\/p>\n\n\n\n<p><strong>CG-0255 offers distinct advantages:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Rapid onset of action<\/strong> \u2013 critical for acute ischemic stroke management<\/li>\n\n\n\n<li><strong>Strong antiplatelet efficacy<\/strong> \u2013 consistent platelet inhibition regardless of genetic metabolic profile<\/li>\n\n\n\n<li><strong>Low inter-patient variability<\/strong> \u2013 predictable pharmacokinetics across diverse patient populations<\/li>\n\n\n\n<li><strong>Minimal drug-drug interactions<\/strong> \u2013 reduced risk of adverse interactions with commonly co-administered medications<\/li>\n\n\n\n<li><strong>Dual formulation flexibility<\/strong> \u2013 seamless transition from IV to oral therapy during hospital-to-home care continuum<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-unmet-need\">Market Opportunity &amp; Unmet Need<\/h2>\n\n\n\n<p>Ischemic stroke represents <strong>70-80% of all stroke cases in China<\/strong>, affecting approximately <strong>2.5 million people annually<\/strong>. Antiplatelet therapy is a cornerstone of both acute treatment and secondary prevention, but current options are limited by metabolic variability and delayed onset.<\/p>\n\n\n\n<p><strong>The Chinese market dynamics favor CG-0255 adoption:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>High prevalence of CYP2C19 loss-of-function alleles in Asian populations (up to 50%)<\/li>\n\n\n\n<li>Growing burden of cardiovascular disease and stroke in aging population<\/li>\n\n\n\n<li>Increasing demand for precision medicine approaches in cerebrovascular care<\/li>\n\n\n\n<li>Limited availability of rapid-onset, reliable antiplatelet options for acute stroke settings<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First-Mover Advantage:<\/strong> World&#8217;s first thiol-based P2Y12 inhibitor positions CureGene at the forefront of next-generation antiplatelet development<\/li>\n\n\n\n<li><strong>Global Potential:<\/strong> Success in China could support international regulatory filings, particularly in other Asian markets with similar genetic profiles<\/li>\n\n\n\n<li><strong>Platform Technology:<\/strong> Thiol-based prodrug design may be applicable to other therapeutic areas requiring reliable metabolic activation<\/li>\n\n\n\n<li><strong>Competitive Differentiation:<\/strong> Addresses fundamental limitations of existing P2Y12 inhibitors that have persisted for over two decades<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approvals, clinical development plans, and therapeutic potential for CG-0255. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai CureGene Pharmaceutical Co., Ltd. announced that China&#8217;s National Medical Products Administration (NMPA) has granted&#8230;<\/p>\n","protected":false},"author":1,"featured_media":65540,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,1575],"class_list":["post-65539","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-curegene-pharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Shanghai CureGene&#039;s CG-0255 Receives NMPA Clearance for Ischemic Stroke Clinical Trial \u2013 First Thiol-Based P2Y12 Inhibitor Overcoming Clopidogrel Resistance - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai CureGene Pharmaceutical Co., Ltd. announced that China&#039;s National Medical Products Administration (NMPA) has granted approval to initiate clinical studies evaluating CG-0255, a Category 1 innovative drug, for the treatment of ischemic stroke. The investigational therapy represents the world&#039;s first P2Y12 receptor inhibitor based on a thiol-based prodrug design, available in both intravenous and oral formulations.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=65539\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shanghai CureGene&#039;s CG-0255 Receives NMPA Clearance for Ischemic Stroke Clinical Trial \u2013 First Thiol-Based P2Y12 Inhibitor Overcoming Clopidogrel Resistance\" \/>\n<meta property=\"og:description\" content=\"Shanghai CureGene Pharmaceutical Co., Ltd. announced that China&#039;s National Medical Products Administration (NMPA) has granted approval to initiate clinical studies evaluating CG-0255, a Category 1 innovative drug, for the treatment of ischemic stroke. The investigational therapy represents the world&#039;s first P2Y12 receptor inhibitor based on a thiol-based prodrug design, available in both intravenous and oral formulations.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=65539\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-18T05:17:09+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-18T05:17:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1801.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65539#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65539\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Shanghai CureGene&#8217;s CG-0255 Receives NMPA Clearance for Ischemic Stroke Clinical Trial \u2013 First Thiol-Based P2Y12 Inhibitor Overcoming Clopidogrel Resistance\",\"datePublished\":\"2026-05-18T05:17:09+00:00\",\"dateModified\":\"2026-05-18T05:17:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65539\"},\"wordCount\":477,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65539#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/1801.webp\",\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"CureGene Pharmaceutical\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65539#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65539\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=65539\",\"name\":\"Shanghai CureGene's CG-0255 Receives NMPA Clearance for Ischemic Stroke Clinical Trial \u2013 First Thiol-Based P2Y12 Inhibitor Overcoming Clopidogrel Resistance - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65539#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65539#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/1801.webp\",\"datePublished\":\"2026-05-18T05:17:09+00:00\",\"dateModified\":\"2026-05-18T05:17:10+00:00\",\"description\":\"Shanghai CureGene Pharmaceutical Co., Ltd. announced that China's National Medical Products Administration (NMPA) has granted approval to initiate clinical studies evaluating CG-0255, a Category 1 innovative drug, for the treatment of ischemic stroke. The investigational therapy represents the world's first P2Y12 receptor inhibitor based on a thiol-based prodrug design, available in both intravenous and oral formulations.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65539#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65539\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65539#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/1801.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/1801.webp\",\"width\":1080,\"height\":608,\"caption\":\"Shanghai CureGene's CG-0255 Receives NMPA Clearance for Ischemic Stroke Clinical Trial \u2013 First Thiol-Based P2Y12 Inhibitor Overcoming Clopidogrel Resistance\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65539#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shanghai CureGene&#8217;s CG-0255 Receives NMPA Clearance for Ischemic Stroke Clinical Trial \u2013 First Thiol-Based P2Y12 Inhibitor Overcoming Clopidogrel Resistance\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Shanghai CureGene's CG-0255 Receives NMPA Clearance for Ischemic Stroke Clinical Trial \u2013 First Thiol-Based P2Y12 Inhibitor Overcoming Clopidogrel Resistance - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai CureGene Pharmaceutical Co., Ltd. announced that China's National Medical Products Administration (NMPA) has granted approval to initiate clinical studies evaluating CG-0255, a Category 1 innovative drug, for the treatment of ischemic stroke. The investigational therapy represents the world's first P2Y12 receptor inhibitor based on a thiol-based prodrug design, available in both intravenous and oral formulations.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=65539","og_locale":"en_US","og_type":"article","og_title":"Shanghai CureGene's CG-0255 Receives NMPA Clearance for Ischemic Stroke Clinical Trial \u2013 First Thiol-Based P2Y12 Inhibitor Overcoming Clopidogrel Resistance","og_description":"Shanghai CureGene Pharmaceutical Co., Ltd. announced that China's National Medical Products Administration (NMPA) has granted approval to initiate clinical studies evaluating CG-0255, a Category 1 innovative drug, for the treatment of ischemic stroke. The investigational therapy represents the world's first P2Y12 receptor inhibitor based on a thiol-based prodrug design, available in both intravenous and oral formulations.","og_url":"https:\/\/flcube.com\/?p=65539","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-18T05:17:09+00:00","article_modified_time":"2026-05-18T05:17:10+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1801.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=65539#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=65539"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Shanghai CureGene&#8217;s CG-0255 Receives NMPA Clearance for Ischemic Stroke Clinical Trial \u2013 First Thiol-Based P2Y12 Inhibitor Overcoming Clopidogrel Resistance","datePublished":"2026-05-18T05:17:09+00:00","dateModified":"2026-05-18T05:17:10+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=65539"},"wordCount":477,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=65539#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1801.webp","keywords":["Clinical trial approval \/ initiation","CureGene Pharmaceutical"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=65539#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=65539","url":"https:\/\/flcube.com\/?p=65539","name":"Shanghai CureGene's CG-0255 Receives NMPA Clearance for Ischemic Stroke Clinical Trial \u2013 First Thiol-Based P2Y12 Inhibitor Overcoming Clopidogrel Resistance - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=65539#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=65539#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1801.webp","datePublished":"2026-05-18T05:17:09+00:00","dateModified":"2026-05-18T05:17:10+00:00","description":"Shanghai CureGene Pharmaceutical Co., Ltd. announced that China's National Medical Products Administration (NMPA) has granted approval to initiate clinical studies evaluating CG-0255, a Category 1 innovative drug, for the treatment of ischemic stroke. The investigational therapy represents the world's first P2Y12 receptor inhibitor based on a thiol-based prodrug design, available in both intravenous and oral formulations.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=65539#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=65539"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=65539#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1801.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1801.webp","width":1080,"height":608,"caption":"Shanghai CureGene's CG-0255 Receives NMPA Clearance for Ischemic Stroke Clinical Trial \u2013 First Thiol-Based P2Y12 Inhibitor Overcoming Clopidogrel Resistance"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=65539#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Shanghai CureGene&#8217;s CG-0255 Receives NMPA Clearance for Ischemic Stroke Clinical Trial \u2013 First Thiol-Based P2Y12 Inhibitor Overcoming Clopidogrel Resistance"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1801.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65539","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=65539"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65539\/revisions"}],"predecessor-version":[{"id":65542,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65539\/revisions\/65542"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/65540"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=65539"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=65539"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=65539"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}